Want to see IMNM full AI Analyst Report?
IMNM Stock Chart & Stats
$22.21
$0.20(0.91%)
At close: 4:00 PM EDT
$22.21
$0.20(0.91%)
Day’s Range― - ―
52-Week Range$8.67 - $28.62
Previous CloseN/A
Volume615.24K
Average Volume (3M)1.56M
Market Cap
$3.18B
Enterprise Value$1.88K
Total Cash (Recent Filing)$520.00M
Total Debt (Recent Filing)$4.59M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Nov 16, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.54
Shares Outstanding113,577,630
10 Day Avg. Volume1,063,226
30 Day Avg. Volume1,564,409
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$36.00Price Target Upside62.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.14
Revenue Forecast (FY)$545.46K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong SolvencyVery low reported debt provides durable solvency and financial flexibility for a clinical-stage biotech. With minimal leverage the company can prioritize R&D and licensing negotiations without near-term debt maturities pressuring cash, extending runway relative to highly leveraged peers.
Antibody Discovery Platform & PipelineA proprietary antibody discovery platform and oncology-focused pipeline are structural strengths: they create repeatable target discovery, enable multiple programs, and increase partnership/licensing optionality. This asset-led model supports long-term value creation if clinical translation succeeds.
Resumed Revenue GenerationHaving restarted revenue, even at a modest scale, signals commercial or partnership traction and reduces sole reliance on grants/financing. Over months this can improve negotiating leverage with partners and provide a foundation to scale collaborations or milestone-based income.
Bears Say
Steep Revenue DeclineA rapid, multi-year revenue contraction weakens the company’s ability to self-fund R&D and signals setbacks in commercialization or partner flows. Durable recovery will require new deals, approvals, or product launches; absent those, revenue shrinkage raises long-term funding risk.
Large Operating & Free Cash BurnSustained, large negative operating and free cash flow consumes cash reserves and forces recurring external financing. Over months this elevates dilution and constrains strategic choices, potentially slowing or delaying clinical programs if capital is not secured on acceptable terms.
Deep, Persistent Losses And MarginsDeep net losses and a negative gross profit reflect structural mismatch between costs and revenue at current scale. This undermines prospects for self-sustaining operations and increases dependency on partners or financing; margin recovery will likely require sustained revenue growth or cost restructuring.
Immunome News
IMNM FAQ
What was Immunome, Inc.’s price range in the past 12 months?
Immunome, Inc. lowest stock price was $8.66 and its highest was $28.62 in the past 12 months.
What is Immunome, Inc.’s market cap?
Immunome, Inc.’s market cap is $3.18B.
When is Immunome, Inc.’s upcoming earnings report date?
Immunome, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 93 days.
How were Immunome, Inc.’s earnings last quarter?
Immunome, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.514 by -$0.136.
Is Immunome, Inc. overvalued?
According to Wall Street analysts Immunome, Inc.’s price is currently Undervalued.
Does Immunome, Inc. pay dividends?
Immunome, Inc. does not currently pay dividends.
What is Immunome, Inc.’s EPS estimate?
Immunome, Inc.’s EPS estimate is -0.6.
How many shares outstanding does Immunome, Inc. have?
Immunome, Inc. has 113,577,630 shares outstanding.
What happened to Immunome, Inc.’s price movement after its last earnings report?
Immunome, Inc. reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.514. Following the earnings report the stock price went up 6.629%.
Which hedge fund is a major shareholder of Immunome, Inc.?
Currently, no hedge funds are holding shares in IMNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunome Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.00 (62.09% Upside)
$36.00 (62.09% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 490.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $103.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
90.82%
Trailing 12-Months
Company Description
Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
IMNM Stock 12 Month Forecast
Average Price Target
$36.00
▲(62.09% Upside)
Technical Analysis
Ownership Overview
1.51% Insiders
36.50% Mutual Funds
5.41% Other Institutional Investors
43.35% Public Companies and
Individual Investors